Cargando…

Treatment of refractory catatonic schizophrenia with low dose aripiprazole

This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Tsuyoshi, Hashimoto, Tasuku, Niitsu, Tomihisa, Kanahara, Nobuhisa, Iyo, Masaomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3473267/ https://www.ncbi.nlm.nih.gov/pubmed/22553911 http://dx.doi.org/10.1186/1744-859X-11-12

Ejemplares similares

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases
por: Muneoka, Katsumasa, et al.
Publicado: (2017)

Treatment of puberty trichotillomania with low-dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2015)

Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia
por: Oishi, Kengo, et al.
Publicado: (2018)

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report
por: Tadokoro, Shigenori, et al.
Publicado: (2017)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
por: Shiina, Akihiro, et al.
Publicado: (2015)

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
por: Shiina, Akihiro, et al.
Publicado: (2010)

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Autistic traits and cognitive profiles of treatment-resistant schizophrenia()
por: Nakata, Yusuke, et al.
Publicado: (2020)

Psychological Distress Symptoms Associated With Life Events in Patients With Bipolar Disorder: A Cross-Sectional Study
por: Sato, Aiko, et al.
Publicado: (2018)

Increased Serum Levels of Oxytocin in ‘Treatment Resistant Depression in Adolescents (TRDIA)’ Group
por: Sasaki, Tsuyoshi, et al.
Publicado: (2016)

Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder
por: Yoshida, Taisuke, et al.
Publicado: (2012)

Correction: Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder
por: Yoshida, Taisuke, et al.
Publicado: (2013)

Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
por: Kanahara, Nobuhisa, et al.
Publicado: (2021)

Relationship between perception and anxiety about COVID-19 infection and risk behaviors for spreading infection: A national survey in Japan
por: Shiina, Akihiro, et al.
Publicado: (2020)

Perception of and anxiety about COVID-19 infection and risk behaviors for spreading infection: an international comparison
por: Shiina, Akihiro, et al.
Publicado: (2021)

Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort
por: Kanahara, Nobuhisa, et al.
Publicado: (2018)

Need for self-medication using over-the-counter psychoactive agents: A national survey in Japan
por: Shiina, Akihiro, et al.
Publicado: (2021)

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
por: Hashimoto, Tasuku, et al.
Publicado: (2015)

Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder
por: Tadokoro, Shigenori, et al.
Publicado: (2011)

Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study
por: Sasaki, Tsuyoshi, et al.
Publicado: (2014)

Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis
por: Kobayashi, Remiko, et al.
Publicado: (2020)

Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study
por: Sasaki, Tsuyoshi, et al.
Publicado: (2014)

Low-dose aripiprazole for refractory burning mouth syndrome
por: Umezaki, Yojiro, et al.
Publicado: (2016)

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases
por: Kanahara, Nobuhisa, et al.
Publicado: (2023)

ECT induced mania in catatonic schizophrenia.
por: Agnihotri, Shruti, et al.
Publicado: (2022)

Wernicke encephalopathy complicating catatonic schizophrenia
por: Rihab, C., et al.
Publicado: (2021)

Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial
por: Hashimoto, Tasuku, et al.
Publicado: (2016)

Catatonic Schizophrenia: Cases with Possible Genetic Predisposition
por: Tariq, Maryam, et al.
Publicado: (2019)

Changes in Self-Regulation-Related Prefrontal Activities in Eating Disorders: A Near Infrared Spectroscopy Study
por: Sutoh, Chihiro, et al.
Publicado: (2013)

Plasma levels of matrix metalloproteinase‐9 (MMP‐9) are associated with cognitive performance in patients with schizophrenia
por: Kudo, Noriko, et al.
Publicado: (2020)

Spontaneous Bladder Rupture in a Catatonic Schizophrenia Patient
por: Miyakoshi, Megumi, et al.
Publicado: (2023)

Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia
por: Kudo, Noriko, et al.
Publicado: (2018)

Salivary Alpha-Amylase Activity Levels in Catatonic Schizophrenia Decrease after Electroconvulsive Therapy
por: Kanayama, Misako, et al.
Publicado: (2018)

PS64. Psychiatrists' thinking about how to prescribe psychotropic drugs in out-patients with major depressive disorder and bipolar disorder in general clinical practice compared to the evidence-based guidelines.
por: Koseki, Maiko, et al.
Publicado: (2016)

A case of Hallervorden-Spatz disease presenting as catatonic schizophrenia
por: Pawar, Yogesh, et al.
Publicado: (2013)

Onset Pattern and Long-Term Prognosis in Schizophrenia: 10-Year Longitudinal Follow-Up Study
por: Kanahara, Nobuhisa, et al.
Publicado: (2013)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_928vrbit8mpl24513ao5imu2ku